IP Library › Granted Patent US 12,205,680
Granted Patent B2
US 12,205,680 · App. 16/290,713 · Granted Jan 21, 2025

Multivariate spectral analysis and monitoring for biomanufacturing

Inventors: Dhanuka Pulasthi Wasalathanthri (Fiskdale, MA); Jagdish C. Tewari (Bridgewater, NJ); Xuezhen Kang (Bridgewater, NJ); Marina Hincapie (Bridgewater, NJ); Shawn L. Barrett (Bridgewater, NJ); Julie Susanne Pollock (Bridgewater, NJ)
Assignee: Genzyme Corporation
G16C20/10C07K1/16C12M21/14C12M37/00C12M41/48C12M47/12G01N21/3577G01N21/552G01N30/46G01N30/78G01N30/86B01D15/1814B01D15/1871G01N2021/3595G01N2021/8416G01N2030/8813G01N2030/8886G01N2201/129
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,205,680
App. No.
16/290,713
Granted
Jan 21, 2025
Kind
B2
Abstract

The disclosure features methods that include obtaining a vibrational spectrum of a solution in a biological manufacturing system, analyzing the vibrational spectrum using a first chemometrics model to determine a value of a first quality attribute associated with the solution, analyzing the vibrational spectrum using a second chemometrics model to determine a value of a second quality attribute associated with the solution, and adjusting at least one parameter of a purification unit of the biological manufacturing system based on at least one of the values of the first and second quality attributes.

Claims (26)

1. A method, comprising:

obtaining a vibrational spectrum of a solution comprising a biological product in a biological manufacturing system;

analyzing the vibrational spectrum using a first chemometrics model to determine a value of a first quality attribute associated with the solution;

analyzing the vibrational spectrum using a second chemometrics model to determine a value of a second quality attribute associated with the solution; and

adjusting at least one parameter of a chromatography column of a purification unit of the biological manufacturing system based on at least one of the values of the first and second quality attributes,

wherein the biological product comprises at least one member selected from the group consisting of:

a protein-based therapeutic substance comprising at least one of a protein, a peptide, an antibody, and an enzyme;

a nucleic acid-based drug substance comprising at least one of DNA, a plasmid, an oligonucleotide, an aptamer, a DNAzyme, an RNA aptamer, an RNA decoy, a microRNA fragment, and a small interfering RNA fragment; and

a gene therapy drug substance.

2. The method of claim 1 , wherein the first and second quality attributes are each independently selected from the group consisting of product quality attributes, product-related impurities, and process-related impurities, for a biological product produced by the biological manufacturing system.

3. The method of claim 1 , wherein obtaining the vibrational spectrum comprises directing radiation to be incident on the solution and measuring attenuated totally reflected radiation from the solution.

4. The method of claim 3 , further comprising measuring the attenuated totally reflected radiation from the solution while the solution is flowing relative to a radiation window.

5. The method of claim 1 , wherein the first chemometrics model comprises a first set of principal vibrational components correlated with the first quality attribute.

6. The method of claim 5 , wherein analyzing the vibrational spectrum using the first chemometrics model comprises calculating the first quality attribute value based on the first set of principal vibrational components.

7. The method of claim 6 , wherein the first and second sets of principal vibrational components have no members in common.

8. The method of claim 1 , wherein the solution comprises a solution discharged from a purification unit of the biological manufacturing system.

9. The method of claim 8 , further comprising purifying the solution in the purification unit prior to obtaining the vibrational spectrum of the solution.

10. The method of claim 1 , further comprising obtaining the vibrational spectrum by measuring radiation from the solution as the solution flows between a first purification unit and a second purification unit of the biological manufacturing system.

11. The method of claim 1 , further comprising obtaining the vibrational spectrum by measuring radiation from the solution after the solution flows out of a final purification unit of the biological manufacturing system.

12. The method of claim 1 , wherein the solution is a first solution, the method further comprising:

obtaining a vibrational spectrum of a second solution in the biological manufacturing system;

analyzing the vibrational spectrum of the second solution using the first chemometrics model to determine a value of the first quality attribute for the second solution; and

analyzing the vibrational spectrum of the second solution using the second chemometrics model to determine a value of the second quality attribute for the second solution,

wherein the first solution flows between a first purification unit and a second purification unit of the biological manufacturing system, and the second solution flows between the second purification unit and a third purification unit of the biological manufacturing system.

13. The method of claim 12 , further comprising adjusting the at least one parameter based on at least one of the first and second quality attribute values for the first solution, and the first and second quality attribute values for the second solution.

14. The method of claim 1 , wherein at least one of the first and second quality attributes is selected from the group consisting of concentration, aggregates, charge variant distribution, purity, glycan profile, identity, integrity, protein fragments, nucleic acid fragments, nucleic acid variants, empty capsids, vector impurities, host cell proteins, residual host DNA, residual column ligands, impurity concentration, impurity amount, residual helper virus, residual helper viral proteins, and residual helper viral DNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2020
From: WASALATHANTHRI, DHANUKA PULASTHI; TEWARI, JAGDISH C.; KANG, XUEZHEN; HINCAPIE, MARINA; BARRETT, SHAWN L.; POLLOCK, JULIE SUSANNE
To: GENZYME CORPORATION
Reel/Frame 051797/0311 →
Continuity (4)
Provisional Application 62729402 · Sep 10, 2018
Provisional Application 62673845 · May 18, 2018
Provisional Application 62637891 · Mar 2, 2018
Related Publication 20190272894A1 · Sep 5, 2019
References Cited (68)
US 5360972A · DiFoggio · 1994 [cited by examiner]
US 5985356A · Schultz · 1999 [cited by examiner]
US 8304231B2 · Roll · 2012 [cited by applicant]
US 8502148B2 · Wagner · 2013 [cited by examiner]
US 9041923B2 · Messerchmidt · 2015 [cited by examiner]
US 10352770B2 · Morales Rodriguez · 2019 [cited by examiner]
US 20040048330A1 · Bittner · 2004 [cited by applicant]
US 20060043301A1 · Mantele et al. · 2006 [cited by applicant]
US 20060051874A1 · Reed et al. · 2006 [cited by applicant]
US 20090296075A1 · Hu et al. · 2009 [cited by applicant]
US 20110070602A1 · Thomson · 2011 [cited by examiner]
US 20110081672A1 · Andersen et al. · 2011 [cited by applicant]
US 20140255994A1 · Konstantinov et al. · 2014 [cited by applicant]
US 20140373606A1 · Kraiczek et al. · 2014 [cited by applicant]
US 20180113025A1 · Morales Rodriguez et al. · 2018 [cited by applicant]
US 20180339244A1 · Hubbuch et al. · 2018 [cited by applicant]
US 20190112569A1 · Czeterko et al. · 2019 [cited by applicant]
US 20200124817A1 · Ohmori et al. · 2020 [cited by applicant]
US 20220101953A1 · Wasalathanthri · 2022 [cited by examiner]
CN 101074928 · 2007 [cited by applicant]
CN 103630515A · 2014 [cited by applicant]
CN 104406836 · 2015 [cited by applicant]
CN 106715670 · 2017 [cited by applicant]
DE 4333560A1 · 1995 [cited by applicant]
EP 0206433A2 · 1986 [cited by applicant]
EP 3173782 · 2017 [cited by applicant]
EP 3129460 · 2017 [cited by applicant]
JP H05322747A · 1993 [cited by applicant]
JP 2005140794 · 2005 [cited by applicant]
JP 2008504845 · 2008 [cited by applicant]
JP 2008526203 · 2008 [cited by applicant]
JP 4638153 · 2011 [cited by applicant]
JP 2012520078 · 2012 [cited by applicant]
JP 2013505462 · 2013 [cited by applicant]
TW I553021 · 2016 [cited by applicant]
TW I591782 · 2017 [cited by applicant]
WO WO2014137903 · 2014 [cited by applicant]
WO WO2015155353 · 2015 [cited by applicant]
WO WO2017088979 · 2017 [cited by applicant]
WO WO2017174580 · 2017 [cited by applicant]
English Translation for CN104406836A, Mar. 11, 2015. [cited by examiner]
Bro et al., “Principal component analysis, ”Analytical Methods, 2014, 6:2812-2831. [cited by applicant]
Chatfield et al., “Principal component analysis,” Introduction to Multivariate Analysis, Springer, 1980, 57-81. [cited by applicant]
Haenlein et al., “A Beginner's Guide to Partial Least Squares Analysis,” Understanding Statistics, 2004, 3(4):283-297. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/020355, dated Sep. 8, 2020, 8 pages. [cited by applicant]
Sellin, “Partial Least Squares Analysis,” International Journal of Educational Research, 1986, 10(2):189-200. [cited by applicant]
European Office Action in Patent Application No. 19715277.0, dated Oct. 20, 2020, 4 pages. [cited by applicant]
Office Action in Brazilian Appln. No. BR112020017726-1, dated Aug. 23, 2022, 5 pages (with English translation). [cited by applicant]
Office Action in European Appln No. 19715277.0, dated Jul. 5, 2022, 8 pages. [cited by applicant]
Office Action in Indian Appln. No. 202037042608, dated Aug. 11, 2022, 8 pages. [cited by applicant]
Office Action in Singapore Appln. No. 11202008436V, dated Jan. 10, 2022, 4 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/643,128, dated Feb. 11, 2022, 16 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/643,128, dated May 26, 2023, 15 pages. [cited by applicant]
International Search Report and Written Opinion in Application No. PCT/US2019/020355, dated May 24, 2019, 23 pages. [cited by applicant]
Office Action in Japanese Appln. No. 2020-545704, dated Nov. 22, 2022, 6 pages (with English translation). [cited by applicant]
Office Action in Russian Appln. No. 2020132277, dated Oct. 17, 2022, 19 pages (with English translation). [cited by applicant]
Office Action in U.S. Appl. No. 17/643,128, dated Dec. 19, 2022, 14 pages. [cited by applicant]
Office Action in Australian Appln. No. 2019226568, dated Oct. 10, 2023, 3 pages. [cited by applicant]
Office Action in Korean Appln No. 10-2020-7027993, dated Nov. 29, 2023, 11 pages. [cited by applicant]
Office Action in Brazilian Appln. No. BR112020017726-1, dated May 18, 2023, 8 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 201980028453.6, dated Jun. 24, 2023, 34 pages (with English translation). [cited by applicant]
Office Action in Singapore Appln. No. 11202008436V, dated Jun. 15, 2023, 7 pages. [cited by applicant]
Office Action in Taiwanese Appln. No. 108107091, dated Apr. 26, 2023, 43 pages (with English translation). [cited by applicant]
Office Action in U.S. Appl. No. 17/643,128, dated Oct. 6, 2023, 15 pages. [cited by applicant]
Office Action in Chinese Appln. No. 201980028453.6, mailed on Jun. 12, 2024, 23 pages (with English translation). [cited by applicant]
Office Action in Chinese Appln. No. 201980028453.6, mailed on Nov. 29, 2023, 31 pages (with English translation). [cited by applicant]
Office Action in European Appln No. 19715277.0, mailed on Jun. 21, 2024, 10 pages. [cited by applicant]
Office Action in Indonesian Appln. No. P00202007144, mailed on Nov. 2, 2023, 5 pages (with English translation). [cited by applicant]